Analyst firms · Barclays · VTRS
Barclays VTRS price target and rating history
Viatris Inc. (VTRS) · Health Care
Barclays rates Viatris Inc. (VTRS) Overweight with a $15 price target, as of its latest action on Dec 9, 2025. It has published 3 rating actions on VTRS since April 2023, including 0 upgrades and 2 downgrades. Across 5 firms with a VTRS price target in the last 12 months, the median target is $18. Barclays's $15 is 17% below that.
- Current rating
- Overweight
- Price target
- $15
- Median target, all firms
- $18
- Actions on VTRS
- 3
Barclays price target on VTRS
Every Barclays rating on VTRS
- Dec 9, 2025
- Jun 23, 2023
- Apr 24, 2023
How other firms rate VTRS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Oppenheimer | Outperform | $25 | Sep 23, 2026 |
| Leerink Partners | Outperform | $20 | Sep 9, 2026 |
| UBS | Buy | $18 | Feb 9, 2026 |
| Argus Research | Buy | $15 | Jan 16, 2026 |
| Barclays | Overweight | $15 | Dec 9, 2025 |
Questions about Barclays and VTRS
- What is Barclays's price target for VTRS?
- Barclays's latest stated price target for Viatris Inc. (VTRS) is $15, from its action on Dec 9, 2025.
- What is Barclays's rating on VTRS?
- Barclays rates VTRS Overweight, a bullish rating, as of Dec 9, 2025.
- When did Barclays last change its view on VTRS?
- On Dec 9, 2025, Barclays starts coverage at Overweight, price target $15.
- How does Barclays's VTRS target compare with other analysts?
- Across 5 firms with a VTRS price target in the last 12 months, the median target is $18. Barclays's $15 is 17% below that.
More VTRS rating histories
All Barclays ratingsVTRS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.